Stoke Therapeutics, Inc. - Common Stock (STOK)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — May 16, 2026Investment Snapshot
- Trading 1,843% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- ROE of 0.3% — below-average profitability
- Revenue growing at 405% annually
Stoke Therapeutics, Inc. - Common Stock (STOK) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $1.9 billion . Key value metrics: P/E ratio 1,791.0, P/B ratio 4.74, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Stoke Therapeutics, Inc. - Common Stock — Fundamental Analysis Summary
Stoke Therapeutics, Inc. - Common Stock (STOK) is currently trading 1,843% above its Graham Number of $1.55, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 1,791.0x.
On financial health, STOK shows a moderate Piotroski F-Score of 6/9, and modest return on equity of 0.3% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.17.
StockPik's composite Value Score for STOK is 42/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
STOK shows revenue growing at 405% year-over-year, with earnings growing at 92%.